Some DNA damage-recognition proteins, transcription factors, mismatch repair proteins and DNA polymerases discriminate between cisplatin (CP)- and oxaliplatin (OX)-GG DNA adducts, and this is thought to help explain differences in efficacy, toxiCity and mutageniCity of CP and OX. In addition, differential recognition of CP- and OX-GG adducts by some proteins has been shown to be highly dependent on the sequence context of the Pt-GG adduct. We have postulated that CP- and OX-GG adducts cause differences in the conformation and/or conformational dynamics of the DNA that provide the basis for differential protein recognition of the adducts. We have determined the NMR solution structure of CP-GG adducts, OX-GG adducts and undamaged DNA in the AGGC sequence context, and of OX-GG adducts and undamaged DNA in the TGGT sequence context. We have also employed molecular dynamics (MD) simulations to investigate the conformational dynamics of CP-GG adducts, OX-GG adducts and undamaged DNA in the AGGC and TGGA sequence contexts. These studies showed clear differences in the conformation dynamics between CP- and OX-GG adducts which correlated with the average conformational differences observed in the NMR solution structures and with conformations previously reported for the CP-GG DNA·HMG1a complex. When the conformational dynamics in both sequence contexts were compared it became evident that: (a) the patterns of hydrogen bond formation between Pt-amine-hydrogens and surrounding bases of the DNA were different for CP- and OX-GG adducts; (b) patterns of hydrogen bond formation were also influenced by the DNA sequence context of the Pt-GG adducts, and (c) differences in patterns of hydrogen bond formation were highly correlated with differences in the conformational dynamics of the adduct. Thus, we postulate that patterns of hydrogen bond formation between Pt-amine hydrogens and surrounding DNA bases are different for CP- and OX-GG adducts, and that those differences in hydrogen bond patterns result in DNA conformational differences that allow selective recognition of CP- and OX-GG adducts by a number of proteins that determine the relative cytotoxiCity and mutageniCity of those adducts.
- DNA adducts
- Conformational dynamics
- DNA damage and repair
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Greene MH. Is cisplatin a human carcinogen? J Nat Cancer Inst 1992;84:306–12.
Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429–39.
Silva MJ, Costa P, Dias A, Valente M, Louro H, Boavida MG. Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cells. Environ Mol Mutagen 2005;46:104–15.
Bassett E, King NM, Bryant MF, et al. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Res 2004;64:6469–75.
Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM, Marinus MG. MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 2002;277:1255–60.
Fink D, Nebel S, Aebi S, et al. The role of mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881–6.
Aebi S, Kurdi-Haidar B, Zheng H, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 37;3087–90.
Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841–5.
Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579–85.
Brown R, Hirst GL, Gallagher WM, et al. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 1997;15:45–52.
Wei M, Cohen SM, Silverman AP, Lippard SJ. Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins. J Biol Chem 2001;276:38774–80.
Zhai X, Beckmann H, Jantzen H-M, Essigmann JM. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 1998;37:16307–15.
Coin F, Frit P, Viollet B, Salles B, Egly JM. TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease. Mol Cell Biol 1998;18:3907–14.
Vaisman A, Lim SE, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specifiCity for translesion synthesis past platinum-DNA adducts. Biochemistry 1999;38:11026–39.
Vaisman A, Chaney SG. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. J Biol Chem 2000;27:13017–25.
Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 2000;39:4575–80.
Wu Y, Pradhan P, Havener J, et al. NMR solution structure of an oxaliplatin 1,2-d(GG) intrastrand cross-link in a DNA dodecamer duplex. J Mol Biol 2004;341:1251–69.
Wu Y, Bhattacharyya D, King CL, et al. Solution structures of a DNA dodecamer duplex with and without a cisplatin 1,2-d(GG) intrastrand cross-link: comparison with the same DNA duplex containing an oxaliplatin 1,2-d(GG) intrastrand cross-link. Biochemistry 2007;46:6477–87
Yang D, van Bloom SSGE, Reedijk J, van Bloom JH, Wang AHJ. Structure and isomerization of an intrastrand cisplatin-cross-linked octamer DNA duplex by NMR analysis. Biochemistry 1995;34:12912–20.
Marzilli LG, Saad JS, Kuklenyik Z, Keating KA, Xu Y. Relationship of solution and protein-bound structures of DNA duplexes with the major intrastrand cross-link lesions formed on cisplatin binding to DNA. J Am Chem Soc 2001;123:2764–70.
Herman F, Kozelka J, Stoven V, et al. A d(GpG)-platinated decanucleotide duplex is kinked an extended NMR and molecular mechanics study. Eur J Biochem 1990;194:119–33.
Gelasco A, Lippard SJ. NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) dGpG intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 1998;37:9230–9.
Takahara PM, Frederick CA, Lippard SJ. Crystal structure of the anticancer drug cisplatin bound to duplex DNA. J Am Chem Soc 1996;118:12309–21.
Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999;399:708–12.
Love JJ, Li X, Case DA, Giese K, Grosschedl R, Wright PE. Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature 1995;376:791–5.
Werner MH, Huth JR, Gronenborn AM, Clore GM. Molecular basis of human 46X,Y sex reversal revealed from the three-dimensional solution structure of the human SRY-DNA complex. Cell 1995;81:705–14.
Murphy EC, Zhurkin VB, Louis JM, Cornilescu G, Clore GM. Structural basis for SRY-dependent 46-X,Y sex reversal: modulation of DNA bending by a naturally occurring point mutation. J Mol Biol 2001;312:481–99.
Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastrand cross-links reveal differences in their conformational dynamics. J Mol Biol 2007;373:1123–40.
Editors and Affiliations
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Chaney, S.G. et al. (2009). Differences in Conformation and Conformational Dynamics Between Cisplatin and Oxaliplatin DNA Adducts. In: Bonetti, A., Leone, R., Muggia, F.M., Howell, S.B. (eds) Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60327-459-3_20
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60327-458-6
Online ISBN: 978-1-60327-459-3